Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14574MR)

This product GTTS-WQ14574MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14574MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10033MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ4728MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ14578MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ26MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ11108MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ3918MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ8075MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ15059MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW